Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Dementia Discovery Fund Exceeds Fundraising Goal By $150m

Executive Summary

Private Company Edition: The Dementia Discovery Fund started in 2015 with plans to raise $200m to fund early-stage development of disease-modifying drugs, but recently closed its fundraising with $350m in commitments. Also, Kaleido's $101m Series C is among three recent $100m-plus rounds.

Advertisement

Related Content

Eisai Refocuses AiM As It Builds US Immuno-Dementia Research
Lilly Stays Committed To Alzheimer's, Including Amyloid Hypothesis, Despite Many Failures
IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering
AbbVie Goes Boldly Into Immuno-Neurology With Alector
Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
New CNS-Focused Biotech Cerevance Launches With Takeda Backing
Stealth BioTherapeutics Looks Ahead To Phase III In Mitochondrial Disease
VC Leading $100m Dementia Discovery Fund Reveals New Model
Big pharma joins UK government in Alzheimer's research funding boost

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123314

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel